Core Viewpoint - The Hengqin Guangdong-Macao Deep Cooperation Zone has made significant progress in promoting Macao's economic diversification and integration with Hengqin over the past four years, focusing on institutional innovation, industrial collaboration, and the integration of livelihoods [2][8]. Policy Support - The establishment of the cooperation zone has led to the relocation of companies like Zhenjiankang Medical Technology to Hengqin, benefiting from favorable policies and support [3]. - As of July 2023, there are nearly 60,000 operating entities in the cooperation zone, with Macao-funded enterprises increasing by 57.49% since its inception [3]. Innovation Empowerment - The establishment of the Zhuhai Macao University Science Research Institute has facilitated cross-border research and development, enhancing the integration of Macao's research capabilities with Hengqin's industrial advantages [5][6]. - New regulations have been introduced to facilitate cross-border practice for Macao medical and legal professionals, with 1,669 professionals already practicing in the cooperation zone as of July 2023 [6]. Livelihood Integration - The "Macao New Neighborhood" project has been developed to provide comprehensive living services for Macao residents, with increasing numbers choosing to reside there [7]. - As of June 2023, the number of Macao residents living in the cooperation zone reached 23,749, a year-on-year increase of 30.1%, while those employed in the zone reached 5,762, up 14.1% [8].

Core Viewpoint - The global microwave ablation therapy device market is projected to grow significantly, with a compound annual growth rate (CAGR) of 6.11% from 2025 to 2031, reaching approximately $920.82 million by 2031 [6][20]. Market Size Analysis - The global market for microwave ablation therapy devices is expected to reach $603.97 million in 2024, with China accounting for about 38.46% of the market at $232.30 million [6][8]. - By 2031, the Chinese market is anticipated to grow to $401.04 million, increasing its global market share to 43.55% [6]. Product Type and Application - Multi-channel ablation devices are expected to dominate the market, with a projected share of 77.66% by 2031 [8]. - Hospitals are the primary application area, expected to hold a market share of approximately 93.71% in 2024, with a CAGR of about 6.35% in the coming years [8]. Industry Concentration Analysis - The top five manufacturers are projected to hold over 65.07% of the market share in 2024, indicating a highly concentrated industry [11]. - Major players include Medtronic, Johnson & Johnson, Varian (Siemens), Nanjing Yigao Medical Technology, and Suzhou Baide Medical [11]. Current Industry Status - The industry is witnessing continuous improvements in device performance, including higher power output and better antenna design, which enhance the precision of ablation [12]. - The integration of multi-modal imaging and navigation technologies is improving surgical success rates by allowing for precise planning and real-time navigation of the ablation needle [12]. - The application of artificial intelligence (AI) is becoming more prevalent, aiding in tumor delineation and treatment efficacy assessment [12]. Development Trends - The future of microwave ablation devices is leaning towards increased automation and intelligence, with AI and robotics expected to play significant roles in surgical planning and execution [14]. - There is a trend towards expanding applications beyond traditional tumors to include conditions like epilepsy and arrhythmias, as well as combining microwave ablation with other therapies [14]. - The industry is moving towards specialization and diversification of devices to meet specific clinical needs, including portable and lightweight models for broader accessibility [14]. Policy Analysis - The regulatory landscape is becoming stricter, with policies like the Medical Device Supervision and Administration Regulations ensuring safety and efficacy in the development and production of microwave ablation devices [15]. - The emphasis on quality management systems and clinical trial regulations is pushing companies to enhance their R&D capabilities and product quality [15][17].

Group 1: Company Developments - Hengqin Bihua Medical Laboratory successfully passed the ISO15189 accreditation site review, indicating that its quality management system and testing capabilities meet international standards [5] - Zhenjiankang Company received NMPA Class III medical device registration for two innovative products, bringing its total to seven Class III and four Class II medical device registrations [6] - Guangdong Taiwen Biological Engineering Co., Ltd. obtained a Class II medical device production license, marking compliance with national regulatory requirements in the field of in vitro diagnostic reagents [7] Group 2: Industry Initiatives - The dual-currency payment pilot program has expanded to six key commercial areas in Hengqin, facilitating small payments in both RMB and MOP, enhancing consumer experience [8] - The revised management measures for the Hengqin Guangdong-Macao Deep Cooperation Zone government investment fund were published, effective from August 13, 2025, focusing on key industry projects [9] - The newly issued support measures for financing development of small and micro enterprises in Hengqin include interest subsidies and risk compensation, with a maximum single financing risk compensation of 7.2 million yuan [10][11]